17 hrs ago
AstraZeneca PLC, Bristol-Myers Squibb Company's Fat Disorder Drug May ...
U.S. Food and Drug Administration staff said on Tuesday they were wary about the benefits versus the risks of AstraZeneca and Bristol-Myers Squibb's new diabetes drug dapagliflozin.
Sun Dec 08, 2013
Pharmaceutical Sales Specialist - CV Speciality PR_D3 - North, PR
DESCRIPTION: External Summary of Primary Responsibilities: - Function independently with a high degree of sales proficiency.
Fri Dec 06, 2013
AstraZeneca Stock Rating Reaffirmed by Citigroup Inc.
's stock had its "neutral" rating restated by equities research analysts at Citigroup Inc. in a research note issued to investors on Friday, Analyst Ratings Net reports.
Thu Dec 05, 2013
BRIEF-EU approves AstraZeneca's four-strain flu vaccine Fluenz Tetra
AstraZeneca PLC : * European Commission approves intranasal four-strain influenza vaccine Fluenz Tetra * Follows a positive opinion from the Committee for Medicinal Products for Human Use on 19 September 2013 * Source text for Eikon: * For more news, please click here We welcome comments that advance the story through relevant opinion, anecdotes, ... (more)
Wed Dec 04, 2013
AstraZeneca PLC Said To Be Eyeing Forest Laboratories, Inc. Takeover Bid
AstraZeneca is considering a takeover bid for Forest Laboratories of the US, according to a Financial Times report which cites people close to two companies.
Tue Dec 03, 2013
The Globe and Mail
Apotex ordered to pay AstraZeneca $76-million in damages
A U.S. federal judge has awarded AstraZeneca PLC $76-million in damages from generic drug manufacturer Apotex Inc. for infringing upon patents for AstraZeneca's blockbuster heartburn drug, Prilosec, between 2003 and 2007.
Mon Dec 02, 2013
AstraZeneca Target of Unusually Large Options Trading
Shares of AstraZeneca saw some unusual options trading activity on Friday. Investors purchased 1,621 put options on the company, Analyst Ratings Network.com reports.
Wed Nov 27, 2013
Updated statin guidelines give AstraZeneca the upper hand: Barron's
New guidance from the AHA on how doctors should go about facilitating a reduction in their patients' risk of heart attack and stroke "marks the biggest shift in cardiovascular-disease prevention in 30 years," Johanna Bennett writes.
Tue Nov 26, 2013
AstraZeneca: A Positive Future Awaits This Company
Biopharmaceutical companies witness their share prices sky rocket following the approval of a drug or a positive review.
Owner of AstraZeneca PLC Site, Loughborough In "Advanced Talks" With Would-Be Tenant
AstraZeneca isn't the only one expanding in jobs, others are hiring too! Check it out! A marketing push is under way to attract world-class businesses to a major science and technology park.
Mon Nov 25, 2013
AstraZeneca - Strengthening Oncology Segment
In its Oncology segment, AstraZeneca recently initiated the late-stage clinical study of "Selumetinib", its MEK inhibitor, which has the potential to block proteins that are responsible for developing cancerous cells.
Sat Nov 23, 2013
AstraZeneca Downgraded to "Neutral" at Ubs Ag
They currently have a GBX 3,400 target price on the stock, down from their previous target price of GBX 3,600 .
Volume Sizzlers - AstraZeneca plc (ADR) (NYSE:AZN), Cobalt...
StockMarketIntel.com issues a special report on the following stocks: AstraZeneca plc , Cobalt International Energy, Inc. , CA, Inc. , The Kroger Co.
Fri Nov 22, 2013
Horizon Discovery Ltd. And AstraZeneca PLC Win ???Licensing Deal Of...
Horizon Discovery has won "Licensing Deal of the Year" at the Scrip Awards 2013, for their agreement with AstraZeneca to explore Horizon's first-in-class kinase target program HD-001 as a means of developing novel therapies for multiple cancer types.
FTSE 100 movers: AstraZeneca rises on drug recommendation, TUI sinks
Shares in biopharmaceutical business AstraZeneca received a boost on Friday afternoon after the company, alongside sector peer Bristol-Myers Squibb, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency had recommended approval of Xigduo, a treatment for adult type two diabetic patients.
Xigduoa (dapagliflozin and metformin hydrochloride) Receives Positive ...
Xigduo a Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes )-- AstraZeneca and Bristol-Myers Squibb today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Xigduo a for adults aged 18 and older with type 2 ... (more)
Thu Nov 21, 2013
Midday Market Stats: Dow Jones Industrial Average Surges On Employment Data
The Dow Jones Industrial Average has tacked on 87.7 points, or 0.6%, to 15,988.54 , after initial jobless claims fell more sharply than expected to a seasonally adjusted 323,000, in the week ended Nov. 16. Meanwhile, the producer price index declined 0.2% in October from the previous month -- in line with economists' estimates -- while the core PPI ... (more)
On a roll: Chapel Hill's Pozen to pay first dividend; CEO to receive $7.56M
On Thursday, Chapel Hill drug developer Pozen announced that it would pay its first-ever dividend to its shareholders, just a few days after the company broke free from a partnership with one drug company it didn't like, and partnered with another company it does like.
FTSE 100 movers: Johnson Matthey tops leaders after results impress
Shares in speciality chemicals company Johnson Matthey leapt to the top of the leaderboard after it reported a robust set of half-year results, powered by a strong performance in Emission Control Technologies ahead of new European legislation and good demand for Process Technologies' products.
Merck & Co. Has 27% Downside Potential, Intrinsic Value Of $35 Per Share
Merck & Co. had a weak Q3 2013. Sales came in 4% lower at $11.0 billion vs. $11.5 billion in Q3 2012 due to patent expiries and unfavorable currency fluctuations.